Wisevoter
San Diego

Resmed Reports Q1 Fiscal 2027 Revenue Growth

The San Diego-based medical device company announced a 6% increase in quarterly revenue to $1.4 billion.

Updated on Oct. 29, 2026 in Corporate Finance

Isometric editorial illustration of arranged medical device components in a grid, representing structured corporate growth.
Resmed reported $1.4 billion in revenue for the first quarter of fiscal 2027, driven by high demand for sleep health devices. AI Illustration. Upload story photo >

Live Poll

Do you prioritize companies with consistent dividend payments when deciding where to invest your money?

Resmed posted strong first-quarter results for fiscal year 2027, with revenue reaching $1.4 billion behind high demand for sleep devices and accessories. The company also declared a quarterly cash dividend of $0.66 per share as part of a $1 billion capital return program.

Why it matters

The company’s growth trajectory continues to be supported by rising demand for respiratory health products and improving margins. Shareholders are seeing direct returns through ongoing dividend payments and share repurchases alongside strategic portfolio changes like the MatrixCare divestiture.

Resmed reported GAAP diluted earnings per share of $2.92, representing a 23% increase, and a non-GAAP gross margin of 62.5%. The company also generated $374 million in free cash flow during the quarter.

The players

Resmed Inc.

This San Diego-headquartered medical device manufacturer specializes in digital health and cloud-connected solutions for sleep apnea and respiratory conditions.

Carol Burt

She is an experienced corporate director who will take on the role of Lead Director at Resmed effective in mid-November.

The details

Growth in the first quarter was fueled by strong sales of masks, accessories, and sleep devices across the company’s product line. Resmed further streamlined its business by completing the divestiture of its MatrixCare division during this period.

Timeline

  1. September 30, 2026 marked the conclusion of the company's first fiscal quarter.

  2. November 11, 2026 is the ex-dividend date for common stockholders and CDI holders.

  3. November 12, 2026 serves as the record date for the announced quarterly cash dividend.

  4. November 15, 2026 is the effective date for the appointment of Carol Burt as Lead Director.

  5. December 17, 2026 is the scheduled payment date for the quarterly cash dividend.

Market Dynamics

This earnings report aligns with the standard quarterly financial disclosure protocols set by the Resmed investor relations and earnings webcast. The performance reflects broader shifts in the healthcare technology sector as companies pivot toward subscription-based accessories and device connectivity.

Shareholders are set to receive a cash dividend of $0.66 per share, providing a direct yield on their investment. Prospective investors may also note the company's forward-looking projection of $12.00 to $12.25 in non-GAAP diluted earnings per share for fiscal 2027.

The takeaway

Resmed continues to emphasize returning capital to shareholders while maintaining steady growth through its core sleep and respiratory device portfolio. Investors should monitor how the company's shift away from the MatrixCare business impacts its operational focus moving forward.

What happens next

The dividend payment is scheduled to occur on December 17, 2026 for eligible shareholders of record as of November 12, 2026.

Further reading

For more on the financial health of local corporations, view the Corporate Finance section.

More information

View the Resmed investor relations and earnings webcast for full details.

Source note: This article includes information reported by The Manila times.

Live Poll

Do you prioritize companies with consistent dividend payments when deciding where to invest your money?